AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00893724
Drug: Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
Trial: NCT01605162
Drug: E7016
RxNorm normalized name: Erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle.
Trial: NCT02820311
Drug: Placebo for TD-4208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: via nebulizer
Trial: NCT04621370
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
Trial: NCT00823095
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
Trial: NCT04527107
Drug: THR-149 0.13mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
Trial: NCT00811135
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 bid po on days 1-14 of each 3-week cycle
Trial: NCT01311791
Drug: Standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as defined per protocol
Trial: NCT00428974
Drug: CF101 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 1 mg q12 hours for 12 weeks
Trial: NCT00428974
Drug: CF101 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 4 mg q12 hours for 12 weeks
Trial: NCT00428974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets q12 hours for 12 weeks
Trial: NCT01714427
Drug: Sterile isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
Trial: NCT00392665
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally twice a day
Trial: NCT00840216
Drug: BIAXIN® XL 500 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg
Trial: NCT02859311
Drug: Withdrawal of therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
Trial: NCT00907907
Drug: CellCept® Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CellCept® Tablets, 500 mg
Trial: NCT01742702
Drug: Salbutamol 400 µg (single dose, no longer given since January 2017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
Trial: NCT02868697
Drug: TauroLock U 25000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
Trial: NCT02868697
Drug: (TauroLock Hep500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
Trial: NCT02329769
Drug: PRO044 SC 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02329769
Drug: PRO044 IV 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02329769
Drug: PRO044 IV 9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04857177
Drug: Lucentis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
Trial: NCT00919503
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01259791
Drug: Individual-specific statin causing myopathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-specific statin causing myopathy vs. placebo
Trial: NCT01259791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03902548
Drug: [18F]P16-129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
Trial: NCT00375648
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02305355
Drug: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03322631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02917889
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
Trial: NCT02917889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
Trial: NCT05930262
Drug: Conventional drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
Trial: NCT04283695
Drug: GX-I7 or [14C] GX-I7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM GX-I7 or IV/IM microdose of GX-I7
Trial: NCT01515657
Drug: Enteric-coated aspirin caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin; once per day for 3 days
Trial: NCT01297270
Drug: BI201335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD BI 201335
Trial: NCT01297270
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01297270
Drug: BI201335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD (once daily) BI 201335
Trial: NCT01297270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01052311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT01052311
Drug: Tredaptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
Trial: NCT03988335
Drug: RIST4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 oral solution
Trial: NCT03988335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT01959074
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aceclofenac 100mg on demand
Trial: NCT02378961
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily with food
Trial: NCT01281566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
Trial: NCT00091715
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 6 months followed by an open-label period
Trial: NCT00858754
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01127724
Drug: vitamin B12 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
Trial: NCT02918019
Drug: MSTT1041A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSTT1041A will be administered as subcutaneous injections.
Trial: NCT02918019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched with MSTT1041A.
Trial: NCT00147563
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03807037
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be administered orally at 1 capsule, twice daily
Trial: NCT02875639
Drug: Yiqi prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02875639
Drug: Huoxue prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02875639
Drug: Buyang huanwu decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02875639
Drug: QISHEN YIQI DRIPPING PILLS
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02875639
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
Trial: NCT02875639
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
Trial: NCT00746395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03793712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral dose, tablets. Once daily. 12 weeks.
Trial: NCT01018979
Drug: TG-0054 (2.24 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Trial: NCT01018979
Drug: TG-0054 (3.14 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Trial: NCT00498173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
Trial: NCT00720109
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00720109
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT00720109
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT00720109
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00720109
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, PO, or IV
Trial: NCT00042861
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00042861
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04031651
Drug: Pudilan Xiaoyan Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
Trial: NCT02199873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03733444
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690, film-coated tablets for oral use.
Trial: NCT03733444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, film-coated tablets for oral use.
Trial: NCT00556322
Drug: Alimta or Taxotere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
Trial: NCT01637272
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
Trial: NCT01899755
Drug: GSK2800528, solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be administered at 3 different dose levels by subcutaneous injection.
Trial: NCT01899755
Drug: Placebo (0.9% w/v Sodium Chloride), solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of. 0.8 mL solution will be administered
Trial: NCT03664063
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Azithromycin single dose - weight based dosing max 2gm
Trial: NCT03978000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water
Trial: NCT02018731
Drug: Metformin and Metformin & L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02018731
Drug: L-Citrulline and Metformin & L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03024060
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
Trial: NCT00047138
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00047138
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003980
Drug: BIBX 1382
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00179582
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02189850
Drug: BLI800 - Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI800 oral solution
Trial: NCT01326494
Drug: Arm 1 Oral Cortico Steroids
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Trial: NCT02423915
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg by vein on Day -8.
Trial: NCT02250781
Drug: Oral ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01537757
Drug: MK-8931
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, administered as oral capsules
Trial: NCT02216461
Drug: High dose of BIBW 2948 BS for oral inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03900871
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
Trial: NCT05080010
Drug: 3 cycles chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
Trial: NCT02803944
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02735369
Drug: 2% OC-10X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% OC-10X
Trial: NCT02735369
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02065752
Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Trial: NCT02065752
Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Trial: NCT03705728
Drug: Remifentanil automatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval
Trial: NCT03705728
Drug: Remifentanil manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
Trial: NCT00003642
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01358864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI201335 for 24 weeks
Trial: NCT03848507
Drug: albumin 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 20% albumin during cystectomy
Trial: NCT00644787
Drug: Fentanyl 1-day transdermal patch (Titration Phase)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
Trial: NCT00644787
Drug: Fentanyl 1-day transdermal patch (Double Blind Phase)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Trial: NCT00644787
Drug: Fentanyl 3-day transdermal patch (Double Blind Phase)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Trial: NCT00644787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Trial: NCT00644787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Trial: NCT04901208
Drug: Placebo pod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine-free pods administered to individuals who use Juul
Trial: NCT00578305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a sterile liquid in single-use vials for iv administration.
Trial: NCT00578305
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes